A5B7-CPG2

A5B7-CPG2 is an antibody-enzyme conjugate designed for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). It consists of the F(ab')2 fragment of the murine monoclonal antibody A5B7, which specifically targets carcinoembryonic antigen (CEA), covalently linked to the bacterial enzyme carboxypeptidase G2 (CPG2) derived from *Pseudomonas* sp. strain RS-16. The therapeutic strategy involves a two-step process: first, the conjugate is administered intravenously and allowed to localize to CEA-expressing tumor cells; second, after systemic clearance of the conjugate, a relatively non-toxic prodrug (such as a benzoic acid mustard or phenol mustard derivative) is administered. CPG2 then cleaves the prodrug at the tumor site to release a potent cytotoxic alkylating agent, thereby minimizing systemic toxicity while maximizing local anti-tumor effect. It has been primarily investigated for the treatment of colorectal cancer in Phase 1 clinical trials.

Other names

F(ab')2-A5B7-CPG2A5B7-carboxypeptidase G2 conjugateA-5B7-carboxypeptidase G2 conjugateA 5B7-carboxypeptidase G2 conjugateanti-CEA antibody-carboxypeptidase G2 conjugate